Provided by Tiger Trade Technology Pte. Ltd.

Ocugen

1.02
-0.0050-0.49%
Post-market: 1.040.0200+1.96%19:59 EDT
Volume:6.47M
Turnover:6.67M
Market Cap:345.29M
PE:-4.00
High:1.06
Open:1.04
Low:1.01
Close:1.03
52wk High:2.73
52wk Low:1.01
Shares:338.52M
Float Shares:327.56M
Volume Ratio:0.46
T/O Rate:1.98%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2551
EPS(LYR):-0.2260
ROE:-660.00%
ROA:-48.44%
PB:-20.86
PE(LYR):-4.51

Loading ...

Ocugen CEO Shankar Musunuri Sells Common Shares Worth $589,430.24

Reuters
·
Yesterday

Ocugen Inc. Stock Slips 3.8%, Underperforms Market

Dow Jones
·
Sep 11

Analysts Offer Insights on Healthcare Companies: Zymeworks (ZYME), Axsome Therapeutics (AXSM) and Ocugen (OCGN)

TIPRANKS
·
Sep 10

Ocugen is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Sep 10

Ocugen price target lowered to $9.50 from $10 at H.C. Wainwright

TIPRANKS
·
Sep 10

Ocugen, Inc. : H.c. Wainwright Cuts Target Price to $9.5 from $10

THOMSON REUTERS
·
Sep 10

Ocugen to Share Ophthalmic Gene Therapy Progress

TIPRANKS
·
Sep 09

Ocugen Inc. Stock Falls Tuesday, Underperforms Market

Dow Jones
·
Sep 09

Ocugen Inc. Stock Rises Thursday, Outperforms Market

Dow Jones
·
Sep 04

Ocugen Doses First Patient in Trial of Potential Eye Disease Drug

MT Newswires Live
·
Sep 01

Ocugen - Bla Filing for Ocu410 Anticipated in 2028

THOMSON REUTERS
·
Sep 01

Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of Ocu410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

THOMSON REUTERS
·
Sep 01

Ocugen Inc. Stock Falls Thursday, Underperforms Market

Dow Jones
·
Aug 28

Ocugen Inc. Stock Rises Tuesday, Outperforms Market

Dow Jones
·
Aug 26

Ocugen to Present Modifier Gene Therapy Platform at September Investor Conferences

Reuters
·
Aug 25

Ocugen Inc. Stock Falls Monday, Underperforms Market

Dow Jones
·
Aug 25

Ocugen’s Earnings Call Highlights Risk-Reward Inflection

TIPRANKS
·
Aug 21

Ocugen Inc. Stock Falls 6.1%, Underperforms Market

Dow Jones
·
Aug 21

Ocugen Inc. Stock Rises 10.4%, Outperforms Market

Dow Jones
·
Aug 20

Ocugen’s Phase 3 Gene Therapy Trial Targets High-Value Dry AMD Market

TIPRANKS
·
Aug 20